Showing results (71-80 of 87) with videos related to
Sort By:
Pageof 9
Blood Cancer Discovery|January 11, 2022
Modulation of CD22 Protein Expression in Childhood Leukemia by Pervasive Splicing Aberrations: Implications for CD22-Directed ImmunotherapiesSisi Zheng, Elisabeth Gillespie, Ammar S Naqvi, et al.Haematologica|November 27, 2025
Hematopoietic cell transplantation after CD19-directed CAR T-cell therapy for remission consolidation or relapse treatment in pediatric acute lymphoblastic leukemiaRegina M Myers, Yimei Li, Hongyan Liu, et al.Blood Advances|February 22, 2024
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemiaRegina M Myers, Kaitlin Devine, Yimei Li, et al.Blood Advances|November 19, 2019
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapyVinodh Pillai, Kavitha Muralidharan, Wenzhao Meng, et al.Nature Reviews. Clinical Oncology|January 23, 2026
The quintessential role for CAR T cell therapy in children, adolescents and young adults with cancerLiora Schultz, Kevin McNerney, Adam J Lamble, et al.Antimicrobial Agents and Chemotherapy|May 25, 2021
Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric PatientsAntonio C Arrieta, Michael Neely, J Christopher Day, et al.Leukemia|June 26, 2026
Plasticity under pressure: biology and detection of lineage switch in acute leukemiaAlexandra E Kovach, Yang-Yang Ding, Adam J Lamble, et al.Cancer Discovery|April 15, 2016
Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaDavid T Teachey, Simon F Lacey, Pamela A Shaw, et al.JCO Oncology Practice|September 19, 2025
AML Care at Home: An Evidence-Based Toolkit to Personalize the Care Setting for Recovery From Pediatric AML ChemotherapyAlix E Seif, Sara L McDonough, Emily M Becker-Haimes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 12, 2021
Blinatumomab Nonresponse and High-Disease Burden Are Associated With Inferior Outcomes After CD19-CAR for B-ALLRegina M Myers, Agne Taraseviciute, Seth M Steinberg, et al.Pageof 9